Fisher B J, Leighton C C, Vujovic O, Macdonald D R, Stitt L
Department of Radiation Oncology, London Regional Cancer Center, London, Ontario, Canada.
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10. doi: 10.1016/s0360-3016(01)01705-9.
To document the incidence of tumor progression in pediatric patients with low-grade gliomas (LGGs), with particular emphasis on those patients who did not receive postoperative chemotherapy or radiotherapy (RT).
A database of 128 patients with histologically confirmed LGGs (World Health Organization Grade I-II), age <or=18 years, who had been referred to the London Regional Cancer Center and Dalhousie University between 1979 and 1995, was compiled.
The median follow-up for the 128 patients was 7.3 years. Of the 128 patients, 63 were male and 65 female. The median age was 7.0 years (range 0-18). Twenty-five patients underwent gross complete resection, 63 subtotal resection, and 40 patients biopsy. Ninety-one percent (n = 117) of the tumors were astrocytomas, of which 22 were pilocytic, 3 were oligodendrogliomas, 7 were mixed gliomas, and 1 was a ganglioglioma. Of the 103 subtotally resected patients, 48 received postoperative RT (median dose 59 Gy in 25 fractions) and 10 patients were irradiated at the time of tumor progression. The 5-year overall survival was 86%, cause-specific survival 88%, and 5-year progression-free survival 79%. The results of the univariate analysis of the overall survival by the Wilcoxon model were statistically significant for Karnofsky performance status (p = 0.03), RT timing (i.e., postoperative vs. deferred; p = 0.05), and tumor location (p = 0.02). The analysis of progression-free survival confirmed the statistical significance of the extent of surgical resection (i.e., complete vs. subtotal resection; p = 0.02). None of the patients who underwent gross complete resections received postoperative RT and none developed tumor recurrence. Of the 103 patients who had subtotal resections, 33 had progression, with a median postprogression survival of 39 months. The rate of tumor progression among the subtotally resected LGG patients who did not receive immediate postoperative RT was 42%. The timing of RT and tumor location lost statistical significance for overall survival when the completely resected patients were excluded from the analysis.
The extent of surgical resection was prognostically significant for progression-free survival but lost significance as a prognostic factor once the complete resection patients were excluded from the analysis. At a median survival of 7.3 years, 42% of the subtotally resected LGG patients who did not receive immediate postoperative RT had tumor progression. No statistically significant difference in survival was seen between the postoperative and deferred RT groups, even though the postoperative RT group was a group with poorer prognostic features (bulky residual tumor postoperatively, Karnofsky performance status <70, and nonhemispheric, noncerebellar tumors), indicating that RT may be beneficial for this particular subset of patients.
记录小儿低级别胶质瘤(LGG)患者肿瘤进展的发生率,尤其着重于那些未接受术后化疗或放疗(RT)的患者。
汇编了一个数据库,其中包含1979年至1995年间转诊至伦敦地区癌症中心和达尔豪斯大学的128例组织学确诊为LGG(世界卫生组织I-II级)、年龄≤18岁的患者。
128例患者的中位随访时间为7.3年。128例患者中,男性63例,女性65例。中位年龄为7.0岁(范围0 - 18岁)。25例患者接受了大体全切,63例次全切,40例患者接受活检。91%(n = 117)的肿瘤为星形细胞瘤,其中22例为毛细胞型,3例为少突胶质细胞瘤,7例为混合性胶质瘤,1例为节细胞胶质瘤。在103例次全切的患者中,48例接受了术后放疗(中位剂量59 Gy,分25次),10例患者在肿瘤进展时接受放疗。5年总生存率为86%,病因特异性生存率为88%,5年无进展生存率为79%。通过Wilcoxon模型对总生存进行单因素分析的结果显示,卡氏功能状态(p = 0.03)、放疗时机(即术后与延迟放疗;p = 0.05)和肿瘤位置(p = 0.02)具有统计学意义。无进展生存分析证实了手术切除范围(即全切与次全切;p = 0.02)的统计学意义。所有接受大体全切的患者均未接受术后放疗,且无一例出现肿瘤复发。在103例次全切的患者中,33例出现进展,进展后中位生存时间为39个月。未接受术后即刻放疗的次全切LGG患者中肿瘤进展率为42%。当将完全切除的患者排除在分析之外时,放疗时机和肿瘤位置对总生存失去统计学意义。
手术切除范围对无进展生存具有预后意义,但一旦将完全切除的患者排除在分析之外,作为预后因素的意义就会丧失。在中位生存时间为7.3年时,未接受术后即刻放疗的次全切LGG患者中有42%出现肿瘤进展。术后放疗组和延迟放疗组在生存方面未见统计学显著差异,尽管术后放疗组是预后特征较差的一组(术后有大量残留肿瘤、卡氏功能状态<70以及非半球、非小脑肿瘤),这表明放疗可能对这一特定亚组患者有益。